

DAFTAR PUSTAKA

- Acierno, C., Caturano, A., Pafundi, P. C., Nevola, R., Adinolfi, L. E., & Sasso, F. C. (2020). Nonalcoholic fatty liver disease and type 2 diabetes: Pathophysiological mechanisms shared between the two faces of the same coin. *Exploration of Medicine*, 1(5), 287-306.
- Aiello, F. I., Bajo, M., Marti, F., Gadano, A., & Musso, C. G. (2017). Model for End-stage Liver Disease (MELD) score and liver transplant: benefits and concerns. *AME Medical Journal*, 2(11).
- American Association for the Study of Liver Diseases (AASLD). (2024). *Hepatotoxic Drug Management in Cirrhosis*. Hepatology Updates.
- Berumen J, Baglieri J, Kisseleva T, Mekeel K. (2021). Liver fibrosis: Pathophysiology and clinical implications. *WIREs Mech Dis*. 2021 Jan;13(1):e1499.
- Bril F, Cusi K, Khan R, Newsome P. N. (2018). Modulation of Insulin Resistance in nonalcoholic fatty liver disease. *Hepatology*. Des; 70(2): 711 - 24.
- BPOM RI. (2020) "Modul Farmakovigilans Untuk Tenaga Profesional Kesehatan Proyek 'Ensuring Drug and Food Safety.'" Badan Pengawas Obat dan Makanan (BPOM) RI 2020 : 19-21.
- Cai Y, Zhou L, Zhao X, dkk. (2024). Effectiveness and safety of carvedilol in cirrhotic patients with portal hypertension: A multicenter prospective study. *Journal of Hepatology Research*, 16(3), 210–219.
- Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*, 67(1), 328–357.
- Chen, Y., Zhang, H., & Liu, X. (2024). *Effectiveness and Safety of Spironolactone in Cirrhosis with Ascites: A Review*. *Journal of Hepatic Medicine*, 18(2), 55–63.
- Efmisa, A. K., Armenia, A., & Almasdy, D. (2023). Penggunaan Obat Berpotensi Hepatotoksik Pada Pasien Sirosis hati: Suatu Telaahan. *Journal of Pharmaceutical and Sciences*, 766-771.
- El-Khateeb E, Darwich AS, Achour B, Athwal V, Rostami Hodgegan A. (2021). Review article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment. *Aliment Pharmacol Ther*; 54: 388–401.

- Eslam, M., Sanyal, A. J., George, J., & International Consensus Panel (2020). MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology*, 158(7), 1999–2014.e1.
- European Association for the Study of the Liver (EASL). (2025). *Clinical Practice Guidelines: Management of Decompensated Cirrhosis*.
- Friedman, S.L., Neuschwander-Tetri, B.A., & Rinella, M. (2018). Mechanisms of NAFLD development and therapeutic strategies. *Nat Med* 24, 908–922. <https://doi.org/10.1038/s41591-018-0104-9>
- Gangopadhyay, A., Ibrahim, R., Theberge, K., May, M., & Houseknecht, K. L. (2022). Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines. *Frontiers in neuroscience*, 16, 1042442.
- Gastroenterology Review. (2025). *Comparative Efficacy of Carvedilol and Propranolol in Portal Hypertension Management*. *Gastroenterology Rev*, 42(1), 12–20.
- Garcia-Tsao G, dkk. (2022). Baveno VII Workshop on Portal Hypertension. *J Hepatol*.
- Garcia-Tsao G, Bosch J, Abraldes JG, dkk. (2022). Portal Hypertension in Cirrhosis: Baveno VII Consensus Workshop. *Journal of Hepatology*, 77(4), 1084–1105.
- Hammer GD, McPhee SJ. 2020. Pathophysiology of Disease: An Introduction to Clinical Medicine, 8e.
- Huang J, dkk. (2024). *Loop Diuretic Safety in Liver Cirrhosis: A Clinical Review*. *J Hepatol Pharmacol*.
- Jha, B. K., Sherpa, M. L., Imran, M., Mohammed, Y., Jha, L. A., Paudel, K. R., & Jha, S. K. (2023). Progress in understanding metabolic syndrome and knowledge of its complex pathophysiology. *Diabetology*, 4(2), 134-159.
- Juanola, O., Martínez-López, S., Francés, R., & Gómez-Hurtado, I. (2021). Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. *International journal of environmental research and public health*, 18(10), 5227.
- Kiapidou, S., Liava, C., Kalogirou, M., Akriviadis, E., & Sinakos, E. (2020). Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know?. *Annals of Hepatology*, 19(2), 134-144.

- Klop, B., Elte, J. W., & Cabezas, M. C. (2013). Dyslipidemia in obesity: mechanisms and potential targets. *Nutrients*, 5(4), 1218–1240.
- Lamichhane, G., Lee, D. Y., Franks, R., Olawale, F., Jin, J. B., Egan, J. M., & Kim, Y. (2024). Curcumin-Rich Diet Mitigates Non-Alcoholic Fatty Liver Disease (NAFLD) by Attenuating Fat Accumulation and Improving Insulin Sensitivity in Aged Female Mice under Nutritional Stress. *Biology*, 13(7), 472.
- Lopez M, dkk. (2025). Acetaminophen Safety in Liver Dysfunction: New Guidelines for Dosing. *Liver Clin Pract*.
- Maharani, B. N. P., Hendriani, A. D., & Iswari, P. W. P. (2023). Liver Cirrhosis: Pathophysiology, Diagnosis, and Management. *Jurnal Biologi Tropis*, 23(1), 457–463. <https://doi.org/10.29303/jbt.v23i1.5763>
- Malnick, S. D. H., Alin, P., Somin, M., & Neuman, M. G. (2022). Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different. *International journal of molecular sciences*, 23(24), 16226.
- Mamone G, Cortis K, Sarah A, Caruso S, Miraglia R. (2018). Hepatic morphology abnormalities: beyond cirrhosis. *Abdom Radiol*. 43(7):1612-1626.
- Mylavarapu, M., Kalpeshbhai, P. N., Hien, V. T. T., Patel, P., & Assefi, M. (2022). Comparison of the Prognostic Value of the Child Pugh and MELD Scoring Systems in Cirrhosis-A Systematic Review. *Journal of Critical Care & Emergency Medicine*. SRC/JCCEM-120.
- Nassir, F. (2022). NAFLD: mechanisms, treatments, and biomarkers. *Biomolecules*, 12(6), 824.
- Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., ... & Doo, E. (2015). Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *The Lancet*, 385(9972), 956-965.
- Niranjan, S., Phillips, B. E., & Giannoukakis, N. (2023). Uncoupling hepatic insulin resistance - hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes. *Frontiers in endocrinology*, 14, 1193373.
- Nurdin, I., & Hartati, S. (2019). *Metodologi penelitian sosial*. Media Sahabat Cendekia.
- Nusrat, S., Khan, M. S., Fazili, J., & Madhoun, M. F. (2014). Cirrhosis and its complications: evidence based treatment. *World journal of gastroenterology*, 20(18), 5442–5460.

- Oh, K. J., Lee, D. S., Kim, W. K., Han, B. S., Lee, S. C., & Bae, K. H. (2016). Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines. *International journal of molecular sciences*, 18(1), 8. <https://doi.org/10.3390/ijms18010008>.
- Prikhodko, V. A., Bezborodkina, N. N., & Okovityi, S. V. (2022). Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. *Biomedicines*, 10(2), 274.
- Runyon BA, AASLD Practice Guidelines. (2021). Management of Adult Patients with Ascites Due to Cirrhosis: An Update. *Hepatology*, 74(2), 923–934.
- Reiberger T, Mandorfer M. (2021). Beta-blocker therapy in portal hypertension: Carvedilol and beyond. *Hepatology International*, 15(4), 859–871.
- Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, and Smith AD. 2009. Liver Biopsy. *Hepatology*, March 2009.p1017-1044
- Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., ... & Robuck, P. R. (2010). Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *New England Journal of Medicine*, 362(18), 1675-1685.
- Sharma B & John S. (2021). Hepatic Cirrhosis. *Treasure Island (FL): StatPearls Publishing*.
- Sharma P. (2022). Value of Liver Function Tests in Cirrhosis. *Journal of clinical and experimental hepatology*, 12(3), 948–964.
- Singh, S. P., Singh, A., Pati, G. K., Misra, B., Misra, D., Kar, S. K., Panigrahi, M. K., Meher, C., Agrawal, O., Rout, N., Pattnaik, K., Bhuyan, P., & Mohapatra, A. (2020). A Study of Prevalence of Diabetes and Prediabetes in Patients of Non-Alcoholic Fatty Liver Disease and the Impact of Diabetes on Liver Histology in Coastal Eastern India. *Journal of Diabetes Mellitus*, 04(04), 290–296.
- Tan, B. L., Norhaizan, M. E., & Liew, W. P. (2018). Nutrients and Oxidative Stress: Friend or Foe?. *Oxidative medicine and cellular longevity*, 2018, 9719584.
- Takimoto R, dkk. (2024). *Spironolactone-Induced Hyperkalemia in Decompensated Cirrhosis*. BMC Pharmacol Toxicol.
- Triyanti, E., & Weningsih, I. R. (2018). Bahan Ajar Rekam Medis dan Informasi Kesehatan (RMIK) Manajemen Informasi Kesehatan III: Desain Formulir. In Pusat Pendidikan Sumber Daya Manusia Kesehatan (Vol. 59).

Wazir, H., Abid, M., Essani, B., Saeed, H., Ahmad Khan, M., Nasrullah, F., Qadeer, U., Khalid, A., Varrassi, G., Muzammil, M. A., Maryam, A., Syed, A. R. S., Shah, A. A., Kinger, S., & Ullah, F. (2023). Diagnosis and Treatment of Liver Disease: Current Trends and Future Directions. *Cureus*, 15(12), e49920.

World Health Organization (WHO). (2024). *Guidelines for the Management of Ascites in Liver Cirrhosis*.

Younossi ZM, Bernstein D, Shiffman ML, Kwo P, Kim WR, Kowdley K V, *dkk*. (2018). Diagnosis and Management of Primary Biliary Cholangitis. *Am J Gastroenterol*;114(1):48–63

Ziolkowska, S., Binienda, A., Jabłkowski, M., Szemraj, J., & Czarny, P. (2021). The interplay between insulin resistance, inflammation, oxidative stress, base excision repair and metabolic syndrome in nonalcoholic fatty liver disease. *International journal of molecular sciences*, 22(20), 11128.

Zoratti, C., Moretti, R., Rebuzzi, L., Albergati, I. V., Di Somma, A., Decorti, G., ... & Giuffrè, M. (2021). Antibiotics and liver cirrhosis: what the physicians need to know. *Antibiotics*, 11(1), 31.

